Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apogee Therapeutics Inc (APGE)

Apogee Therapeutics Inc (APGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for...

APGE : 73.00 (-7.87%)
Stocks Sharply Higher as President Trump Seeks to End Iran War

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.15%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +1.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.22%. June E-mini S&P...

ALK : 38.48 (-0.39%)
GOOGL : 290.44 (-3.85%)
AAPL : 251.64 (+0.06%)
TRI : 87.40 (-4.01%)
TSLA : 383.03 (+0.57%)
VVV : 34.38 (+2.05%)
SPY : 653.18 (-0.34%)
INSM : 139.14 (-3.36%)
DKNG : 23.31 (-2.71%)
META : 592.92 (-1.84%)
EL : 71.48 (-9.85%)
AAL : 10.71 (-0.93%)
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for...

APGE : 73.00 (-7.87%)
Stocks Rally as President Trump Eases Iran Threats

The S&P 500 Index ($SPX ) (SPY ) today is up +2.10%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +2.30%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.19%. June E-mini S&P futures (ESM26...

ALK : 38.48 (-0.39%)
GOOGL : 290.44 (-3.85%)
AAPL : 251.64 (+0.06%)
ADI : 321.83 (+3.09%)
TRI : 87.40 (-4.01%)
TSLA : 383.03 (+0.57%)
WDC : 301.05 (+2.12%)
VVV : 34.38 (+2.05%)
AMD : 205.37 (+1.33%)
SPY : 653.18 (-0.34%)
INSM : 139.14 (-3.36%)
DKNG : 23.31 (-2.71%)
Stocks Rebound as Crude Oil Sinks After President Trump Eases Iran Threats

The S&P 500 Index ($SPX ) (SPY ) today is up +1.73%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.97%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.79%. June E-mini S&P futures (ESM26...

ALK : 38.48 (-0.39%)
GOOGL : 290.44 (-3.85%)
UAL : 93.56 (-0.43%)
AAPL : 251.64 (+0.06%)
DHI : 138.33 (-0.35%)
BLDR : 83.94 (-0.85%)
$IUXX : 24,002.45 (-0.77%)
ZNM26 : 110-225 (+0.25%)
MSFT : 372.74 (-2.68%)
KBH : 52.94 (-0.47%)
TSLA : 383.03 (+0.57%)
APGE : 73.00 (-7.87%)
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients...

APGE : 73.00 (-7.87%)
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class...

APGE : 73.00 (-7.87%)
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway: - APEX Phase 2 Part A 52-week data expected this month - APEX Phase 2 Part...

APGE : 73.00 (-7.87%)
Apogee Therapeutics to Participate in Upcoming March Conferences

SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th...

APGE : 73.00 (-7.87%)
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim...

APGE : 73.00 (-7.87%)

Barchart Exclusives

The Top High-Yield Dividend Stock to Buy Now for Oil Price Protection
As the situation remains tense, this high dividend-paying consumer staple company can be a prudent choice for investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.